comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 00:34:04 - browse：68

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The Pandemic Treaty must support building strong health systems

WSS

With trial win, GSK could get blood cancer drug back on market

30 years of 'Listening to Prozac'

Pediatric cancer treatments threatened by a new FDA policy

ASCO: Palliative care found as helpful given virtually as in person

Will the market for weight loss drugs really reach $100 billion?

Cord blood banking comes at a high cost to babies

focus

comprehensive

hotspot

How one medical school became remarkably diverse

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

New air purifier tech could be key to improving indoor air quality

Letters to First Opinion on caregivers, digital health, and more

Medicare proposal to cover medical devices draws a mixed reaction

Mayo Clinic plans $5B tech

The high cost of giving birth even with insurance

ASCO: AstraZeneca says CAR

Supreme Court strikes down use of affirmative action

Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

UnitedHealth’s Optum accused of antitrust violations in California

Shifting the focus from loneliness to social health

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Cigna, Humana reportedly in talks to merge

FDA's Pazdur wants cancer trials to range beyond China alone

Cord blood banking comes at a high cost to babies

Wikipedia

focus

focus

focus